EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
3.1.3.67 | Acquired Immunodeficiency Syndrome |
28192480 |
mTOR activity in AIDS-related diffuse large B-cell lymphoma. |
ongoing research unassigned |
1 0 |
3.1.3.67 | Acute Kidney Injury |
25844699 |
Xenon Protects Against Septic Acute Kidney Injury via miR-21 Target Signaling Pathway. |
causal interaction unassigned |
1 0 |
3.1.3.67 | Adenocarcinoma |
11146227 |
Absence of PTEN/MMAC1 gene mutations in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats. |
causal interaction diagnostic usage ongoing research unassigned |
3 3 2 0 |
3.1.3.67 | Adenocarcinoma |
12695913 |
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. |
causal interaction diagnostic usage ongoing research unassigned |
4 3 2 0 |
3.1.3.67 | Adenocarcinoma |
16220831 |
Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth. |
causal interaction diagnostic usage ongoing research unassigned |
1 3 4 0 |
3.1.3.67 | Adenocarcinoma |
19007975 |
PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. |
causal interaction unassigned |
1 0 |
3.1.3.67 | Adenocarcinoma |
19242756 |
Expression of FAK and PTEN in Bronchioloalveolar carcinoma and lung adenocarcinoma. |
causal interaction diagnostic usage ongoing research unassigned |
1 1 4 0 |
3.1.3.67 | Adenocarcinoma |
19691991 |
Histologic-Type Specific Role of Cell Cycle Regulators in Non-Small Cell Lung Carcinoma. |
ongoing research unassigned |
4 0 |
3.1.3.67 | Adenocarcinoma |
20661135 |
The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis. |
causal interaction ongoing research unassigned |
1 1 0 |
3.1.3.67 | Adenocarcinoma |
21285871 |
Utilization of Unlabeled Probes for the Detection of Fibroblast Growth Factor Receptor 2 Exons 7 and 12 Mutations in Endometrial Carcinoma. |
causal interaction diagnostic usage ongoing research therapeutic application |
4 2 2 1 |